126 related articles for article (PubMed ID: 8471331)
1. Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma.
Escudier B; Farace F; Angevin E; Triebel F; Antoun S; Leclercq B; Brandely M; Aboudaram A; Nitenberg G; Hercend T
Eur J Cancer; 1993; 29A(5):724-8. PubMed ID: 8471331
[TBL] [Abstract][Full Text] [Related]
2. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
3. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
4. High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer.
Kruit WH; Goey SH; Lamers CH; Gratama JW; Visser B; Schmitz PI; Eggermont AM; Bolhuis RL; Stoter G
J Immunother; 1997 Jul; 20(4):312-20. PubMed ID: 9220321
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2.
Escudier B; Farace F; Angevin E; Charpentier F; Nitenberg G; Triebel F; Hercend T
Eur J Cancer; 1994; 30A(8):1078-83. PubMed ID: 7654433
[TBL] [Abstract][Full Text] [Related]
6. Intensive regimen of cytokines with interleukin-2 and interferon alfa-2b in selected patients with metastatic renal carcinoma.
Négrier S; Mercatello A; Bret M; Merrouche Y; Coronel B; Favrot M; Gaspard M; Dorez D; Philip I; Lanier F
J Immunother Emphasis Tumor Immunol; 1995 Jan; 17(1):62-8. PubMed ID: 7728307
[TBL] [Abstract][Full Text] [Related]
7. A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2.
Wang JC; Walle A; Novogrodsky A; Suthanthiran M; Silver RT; Bander NH; Rubin AL; Stenzel KH
J Clin Oncol; 1989 Dec; 7(12):1885-91. PubMed ID: 2555451
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1.
Donskov F; Jensen NV; Smidt-Hansen T; Brøndum L; Geertsen P
Acta Oncol; 2018 May; 57(5):589-594. PubMed ID: 29392960
[TBL] [Abstract][Full Text] [Related]
9. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.
Fisher RI; Coltman CA; Doroshow JH; Rayner AA; Hawkins MJ; Mier JW; Wiernik P; McMannis JD; Weiss GR; Margolin KA
Ann Intern Med; 1988 Apr; 108(4):518-23. PubMed ID: 3258138
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of metastatic kidney neoplasms with a new interleukin 2 protocol: The experience of the Gustave-Roussy Institute].
Escudier B; Farace F; Théodore C; Angevin E; Court B; Couanet D; Dietrich PY; Culine S; Pallardy M; Hercend T
Bull Cancer; 1995 Apr; 82(4):296-302. PubMed ID: 10846540
[TBL] [Abstract][Full Text] [Related]
11. Lack of efficacy of low-dose subcutaneous recombinant interleukin-2 and interferon-alpha in the treatment of metastatic renal cell carcinoma.
Thiounn N; Mathiot C; Dorval T; Flam TA; Tartour E; Mosseri V; Zerbib M; Fridman WH; Debre B
Br J Urol; 1995 May; 75(5):586-9. PubMed ID: 7613793
[TBL] [Abstract][Full Text] [Related]
12. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
13. High-dose interleukin-2 two days a week for metastatic renal cell carcinoma: a FNCLCC multicenter study.
Escudier B; Ravaud A; Fabbro M; Douillard JY; Négrier S; Chevreau C; Mignot L; Baume D; Dorval T; Vignal F
J Immunother Emphasis Tumor Immunol; 1994 Nov; 16(4):306-12. PubMed ID: 7881640
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer.
Redman BG; Flaherty L; Chou TH; al-Katib A; Kraut M; Martino S; Chen B; Kaplan J; Valdivieso M
J Clin Oncol; 1990 Jul; 8(7):1269-76. PubMed ID: 2113571
[TBL] [Abstract][Full Text] [Related]
15. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.
Thompson JA; Shulman KL; Benyunes MC; Lindgren CG; Collins C; Lange PH; Bush WH; Benz LA; Fefer A
J Clin Oncol; 1992 Jun; 10(6):960-8. PubMed ID: 1588376
[TBL] [Abstract][Full Text] [Related]
16. Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.
Pichert G; Jost LM; Fierz W; Stahel RA
Br J Cancer; 1991 Feb; 63(2):287-92. PubMed ID: 1997108
[TBL] [Abstract][Full Text] [Related]
17. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.
Parkinson DR; Fisher RI; Rayner AA; Paietta E; Margolin KA; Weiss GR; Mier JW; Sznol M; Gaynor ER; Bar MH
J Clin Oncol; 1990 Oct; 8(10):1630-6. PubMed ID: 2213100
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2 in combination with interferon-alpha in disseminated malignant melanoma and advanced renal cell carcinoma. A phase I/II study.
Bergmann L; Weidmann E; Mitrou PS; Runne U; Keilholz U; Bartsch HH; Franks CR
Onkologie; 1990 Apr; 13(2):137-40. PubMed ID: 2197585
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.
Whitehead RP; Ward D; Hemingway L; Hemstreet GP; Bradley E; Konrad M
Cancer Res; 1990 Oct; 50(20):6708-15. PubMed ID: 2208137
[TBL] [Abstract][Full Text] [Related]
20. Metastatic renal cell carcinoma: long-term survival after therapy with high-dose continuous-infusion interleukin-2.
Gold PJ; Thompson JA; Markowitz DR; Neumann S; Fefer A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S85-91. PubMed ID: 9457401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
